Clinical studies of lactobacilli showing ability to survive in the gastrointestinal tract
| Bacteria | Dose | Site | Ref. (Design) |
|---|---|---|---|
| L. acidophilus 821–3 | 1×1010 CFU | Gastrointestinal tract | 15(open study) |
| L. acidophilus B. sp | 1×108 CFU/g (100 g) 1×107 CFU/g (100 g) | Small intestine | 237(open study) |
| L. casei Shirota | 1×108 CFU/mL (100 mL) | Gastrointestinal tract | 238(14-day baseline, ingestion and follow-up periods) |
| L. acidophilus LA02 (DSM 21717) L. rhamnosus LR04 (DSM 16605) L. rhamnosus GG (ATCC 53103) L. rhamnosus LR06 (DSM 21981) B. lactis BS01 (LMG P-21384) | 5×109 CFU (of each) | Gastrointestinal tract | 239(double-blind, randomised, cross-over study) |
| L. plantarum LP01 (LMG P-21021) B. breve BR03 (DSM 16604) | 1×109 CFU (of each) | Gastrointestinal tract | 240(double-blind, randomised, cross-over study) |
| Lakcid® L (L. rhamnosus 573/1, 573 L/2 and 573L3) | 1.2×1010 CFU | Gastrointestinal tract | 241(prospective, double-blinded, placebo-controlled randomised study) |